In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innovation

Set Alert for Innovation

A Phoenix Turn For Tonix: Rising From Phase III Ashes With New PTSD Approach

In an exclusive interview, Seth Lederman, CEO of New York-based Tonix Pharmaceuticals, talks about the company’s R&D rollercoaster ride and how it plans to keep its lead asset on track for approval as a treatment for post-traumatic stress disorder. 

Innovation C-Suite Speaks Research and Development Strategies
Advertisement

Latest From Innovation

One Rare Disease Drug’s Access Journey Across The Globe

Infographic: Vertex, the first company to produce a drug to treat the underlying cause of cystic fibrosis, has fought for fair (and high) prices for its medicines to reflect their value as treatments for the cause of a genetic disease. The company has sought innovative reimbursement agreements for its CF products in various countries.

Rare Diseases Innovation

Pharma’s Digital Directive: Not If, But How

Data science and data analytics offer operational advantages throughout large organizations. And the pharma should approach digital technology pragmatically, first applying the tools to what it already does.

Digital Health Innovation

Aetion: Sealing The Deal With Payers On Real-World Research

As biopharma’s embrace of real-world evidence (RWE) gathers speed, In Vivo looks at one company that is using a mix of prestigious academic, government and non-profit partners to build a credible foundation for acceptance of this research tool in the wider commercial space. 

Innovation Strategy

A Chance To Own The Venous Space: BTG Acquires Novate

Complications with inferior vena cava (IVC) filters and subsequent patient-injury lawsuits have made this a tricky space for medical technology innovators, bu BTG has not been deterred. The UK company has entered the fray with a technology developed by Novate Medical, and as a bioconvertible product BTG believes it has key advantages compared with other offerings. 

Innovation Surgical Procedures

Twist Bioscience: DNA Research Tools Put Fresh Spin On Drug Discovery

Speed and efficiency are fundamental to the success of today’s biopharmaceutical enterprise, but the hunt is still on for transformative technologies to boost pipeline productivity and growth. One answer may lie in the arrival of replicable, synthetic versions of DNA.

Innovation Research and Development Strategies

Partnering In Cell And Gene Therapy Is A Unique Endeavor

Industry and academic representatives shared viewpoints at Biotech Week Boston in September 2018, including what is unique about deal-making in the cell and gene field.

Regenerative Medicine Deals
See All
UsernamePublicRestriction

Register